...
首页> 外文期刊>American Journal of Physiology >Endothelin-1-induced contraction in veins is independent of hydrogen peroxide.
【24h】

Endothelin-1-induced contraction in veins is independent of hydrogen peroxide.

机译:内皮素-1诱导的静脉收缩与过氧化氢无关。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Reactive oxygen species (ROS), such as superoxide and H(2)O(2), are capable of modifying vascular tone, although the response to ROS can vary qualitatively among vascular beds, experimental procedures, and species. Endothelin-1 (ET-1) induces superoxide production, which can be dismutated to H(2)O(2). The RhoA/Rho kinase pathway partially mediates ET-1-induced contraction and recently was implicated in superoxide-induced contraction. We hypothesized that H(2)O(2), not superoxide, mediates venous ET-1-induced contraction. Rat thoracic aorta and vena cava contracted to exogenously added H(2)O(2) (1 microM-1 mM) [maximum aortic contraction = 10 +/- 3% of phenylephrine (10 microM) contraction; maximum venous contraction = 85 +/- 13% of norepinephrine (10 microM) contraction]. (+)-(R)-trans-4-(1-aminoethyl-N-4-pyridil)cyclohexanecarboxamide dihydrochloride (Y-27632, 10 microM), a Rho kinase inhibitor, significantly reduced venous H(2)O(2)-induced contraction (15 +/- 1% of control maximum) and reduced maximum ET-1-induced contraction by 59 +/- 1%. However, neither the H(2)O(2) scavenger catalase (100 and 2,000 U/ml) nor cell permeable polyethylene glycol-catalase (163 and 326 U/ml) reduced ET-1-induced contraction in the vena cava. The catalase inhibitor 3-aminotriazole (3-AT) also had no effect on maximal venous ET-1-induced contraction. Basal H(2)O(2) levels were three times higher in the vena cava than in the aorta (vena cava, 0.74 +/- 0.09 nmol H(2)O(2)/mg protein; aorta, 0.24 +/- 0.05 nmol H(2)O(2)/mg protein). ET-1 (100 nM) increased H(2)O(2) in the vena cava but not in the aorta (vena cava, 154.10 +/- 17.29% of control H(2)O(2); aorta, 83.72 +/- 20.20%). Antagonism of either ET(A) or ET(B) receptors with the use of atrasentan (30 nM) or BQ-788 (100 nM), respectively, reduced ET-1 (100 nM)-induced increases in venous H(2)O(2). In summary, ET-1 increased H(2)O(2) in veins but not arteries, and venous ET-1-induced H(2)O(2) production was independent of the contractile properties of ET-1.
机译:活性氧(ROS),例如超氧化物和H(2)O(2),能够修饰血管张力,尽管对ROS的响应在血管床,实验程序和物种之间可能发生质变。内皮素-1(ET-1)诱导产生超氧化物,该氧化物可歧化为H(2)O(2)。 RhoA / Rho激酶途径部分介导ET-1诱导的收缩,最近与超氧化物诱导的收缩有关。我们假设H(2)O(2),而不是超氧化物,介导ET-1诱导的静脉收缩。大鼠胸主动脉和腔静脉收缩到外源性添加H(2)O(2)(1 microM-1 mM)[最大主动脉收缩=苯肾上腺素(10 microM)收缩的10 +/- 3%;最大静脉收缩=去甲肾上腺素(10 microM)收缩的85 +/- 13%]。 (+)-(R)-反式-4-(1-氨基乙基-N-4-吡啶基)环己烷甲酰胺二盐酸盐(Y-27632,10 microM),Rho激酶抑制剂,可显着降低静脉H(2)O(2) -诱导的收缩(对照最大值的15 +/- 1%)和最大的ET-1诱导的收缩降低59 +/- 1%。但是,无论是H(2)O(2)清除剂过氧化氢酶(100和2,000 U / ml)还是细胞可渗透的聚乙二醇过氧化氢酶(163和326 U / ml)都不会降低腔静脉中ET-1诱导的收缩。过氧化氢酶抑制剂3-氨基三唑(3-AT)对最大静脉ET-1诱导的收缩也没有影响。腔静脉中的基础H(2)O(2)水平比主动脉高三倍(静脉,0.74 +/- 0.09 nmol H(2)O(2)/ mg蛋白;主动脉,0.24 +/- 0.05 nmol H(2)O(2)/ mg蛋白)。 ET-1(100 nM)增加了腔静脉中的H(2)O(2),但没有增加主动脉中的水平(静脉中的H(2)O(2)的154.10 +/- 17.29%;主动脉83.72 + /-20.20%)。分别使用阿特拉森坦(30 nM)或BQ-788(100 nM)拮抗ET(A)或ET(B)受体,减少了ET-1(100 nM)诱导的静脉H(2)升高。 O(2)。总之,ET-1增加静脉中的H(2)O(2),但不增加动脉,而静脉ET-1诱导的H(2)O(2)的产生与ET-1的收缩特性无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号